Ovid Therapeutics Inc. (OVID)

2.39
NASDAQ : Health Technology
Prev Close 2.37
Day Low/High 2.37 / 2.45
52 Wk Low/High 1.53 / 6.82
Avg Volume 492.00K
Exchange NASDAQ
Shares Outstanding 47.69M
Market Cap 113.03M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ovid Therapeutics Announces Positive Initial Data From Ongoing ENDYMION Open-Label Extension Trial Of Soticlestat In People With Rare Epilepsies

Ovid Therapeutics Announces Positive Initial Data From Ongoing ENDYMION Open-Label Extension Trial Of Soticlestat In People With Rare Epilepsies

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare Epilepsies; Initial Data from Phase 2...

Ovid Therapeutics Announces First Patient Randomized In Pivotal Phase 3 NEPTUNE Trial Of OV101 For The Treatment Of Angelman Syndrome

Ovid Therapeutics Announces First Patient Randomized In Pivotal Phase 3 NEPTUNE Trial Of OV101 For The Treatment Of Angelman Syndrome

OV101 May Become the First Medicine for Individuals with Angelman Syndrome; Topline Results Expected in Mid-2020

Ovid Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

Ovid Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.

Ovid Therapeutics Announces Participation In Two Upcoming Investor Conferences

Ovid Therapeutics Announces Participation In Two Upcoming Investor Conferences

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.

Ovid Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Progress

Ovid Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Progress

Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.

Ovid Therapeutics Receives Orphan Drug Designation From The European Commission For OV101 For The Treatment Of Angelman Syndrome

Ovid Therapeutics Receives Orphan Drug Designation From The European Commission For OV101 For The Treatment Of Angelman Syndrome

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the European...

Ovid Therapeutics To Present At The 12th International Epilepsy Colloquium

Ovid Therapeutics To Present At The 12th International Epilepsy Colloquium

First scientific presentation of OV-935 (TAK-935) safety and tolerability data in developmental and epileptic encephalopathies from the Phase 1b/2a clinical trial

Ovid Therapeutics Is Now Oversold (OVID)

Ovid Therapeutics Is Now Oversold (OVID)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Ovid Therapeutics (OVID)

Oversold Conditions For Ovid Therapeutics (OVID)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ovid Therapeutics Is Now Oversold (OVID)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ovid Therapeutics Enters Oversold Territory (OVID)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Fragile X Syndrome

Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Fragile X Syndrome

Second Fast Track Designation for OV101 within Three Months

Oversold Conditions For Ovid Therapeutics (OVID)

Oversold Conditions For Ovid Therapeutics (OVID)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

Represents the second orphan drug designation for this compound being co-developed by Ovid and Takeda